GUERBET |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.4 EUR | +4.32% |
|
+10.65% | +91.79% |
| 26/04 | Guerbet: quarterly sales up by nearly 8 | CF |
| 25/04 | Guerbet SA Provides Earnings Guidance for the Year 2024 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.91 for the current period. Therefore, the company is undervalued.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +91.79% | 502M | B+ | ||
| -5.77% | 14.68B | - | ||
| -40.71% | 2.71B | C- | ||
| -12.92% | 2.44B | - | ||
| -8.78% | 1.51B | - | - | |
| -.--% | 1.12B | - | - | |
| +40.66% | 518M | - | ||
| +11.68% | 239M | C | ||
| +1.67% | 183M | - | ||
| -.--% | 168M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GBT Stock
- Ratings Guerbet
